FDA Approves AstraZeneca's Imfinzi (Durvalumab) In Combination With Chemotherapy For Resectable Early-Stage Non-small Cell Lung Cancer And No Known Epidermal Growth Factor Receptor Mutations Or Anaplastic Lymphoma Kinase Rearrangements
FDA Approves AstraZeneca's Imfinzi (Durvalumab) In Combination With Chemotherapy For Resectable Early-Stage Non-small Cell Lung Cancer And No Known Epidermal Growth Factor Receptor Mutations Or Anaplastic Lymphoma Kinase Rearrangements
FDA批准阿斯利康的伊姆非尼（杜瓦魯莫）與化療聯合治療可手術切除期早期非小細胞肺癌以及沒有已知表皮生長因子受體突變或類脈絡突變。
FDA Approves AstraZeneca's Imfinzi (Durvalumab) In Combination With Chemotherapy For Resectable Early-Stage Non-small Cell Lung Cancer And No Known Epidermal Growth Factor Receptor Mutations Or Anaplastic Lymphoma Kinase Rearrangements
FDA批准阿斯利康的伊姆非尼（杜瓦魯莫）與化療聯合治療可手術切除期早期非小細胞肺癌以及沒有已知表皮生長因子受體突變或類脈絡突變。
資訊熱榜
更新時間